Corporate Banner
Satellite Banner
Technology Networks Header
Monday, December 22, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Vetter Launches New Clinical Syringe Packages
Friday, April 11, 2014
Earlier syringe development may cut time-to-market, increase clinical trial appeal.

Immunovaccine's DepoVax™ Technology Underpins New Experimental Therapy for Cancers
Wednesday, April 09, 2014
IMV vaccine adjuvant technology of choice for Dana-Farber's HPV-related cancer clinical trial.

Epistem Announces Installation of UKs First Bruker Xtreme Imaging System
Tuesday, April 08, 2014
Xtreme system will enable Epistem to expand both the range and throughput of its imaging services.

Vetter to Implement Serialization to Support Track-and-Trace Efforts
Friday, March 28, 2014
Flexible service offering planned to go into effect in 2014.

BioOutsource Launches Flagship Reverse Signaling Apoptosis Bioassay
Tuesday, March 25, 2014
Presents webinar on improving speed to market for Biosimilars.

Kemwell Adds Lyophilization Capability
Saturday, March 22, 2014
Addition of the new freeze drying capability sets the Company on a course to expand business from both new and existing customers.

Catalent Launches ADVASEPT™ Advanced Aseptic Technology
Saturday, March 15, 2014
New technology for glass-free delivery of injectable drugs.

Lab Relocation Specialist Expands Turnkey Solution
Friday, March 07, 2014
Specialist laboratory relocation expert, Andrew Porter Limited, has further expanded its service portfolio.

Almac Adds New Blistering Technology at US Facility
Friday, February 28, 2014
Simple solutions to bridge the gap between clinical and commercial packaging.

<< 1 2 3 4 5 6 7 >>
Showing Results 21 - 30 of 297
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn